Characteristics of long-term responder (LTR) patients (pts) treated with androgen-receptor signaling inhibitors (ARSI) as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC): Real-world evidence from four high-volume institutions.

Authors

null

Orazio Caffo

Santa Chiara Hospital, Trento, Italy

Orazio Caffo , Consuelo Buttigliero , Carlo Cattrini , Davide Bimbatti , Massimiliano Cani , Nicolò Cavasin , Veronica Crespi , Giovanni Farinea , Dzenete Kadrija , Stefania Kinspergher , Eleonora Lai , Francesca Maines , Alessia Mennitto , Antonello Veccia , Giovanni L. Pappagallo , Marco Maruzzo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 164)

DOI

10.1200/JCO.2023.41.6_suppl.164

Abstract #

164

Poster Bd #

E18

Abstract Disclosures

Similar Posters

First Author: Emily Nash Smyth

First Author: Shingo Hatakeyama

Poster

2019 Genitourinary Cancers Symposium

Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).

Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Edmond Michael Kwan

First Author: Simon J. Crabb